khk

KHK-IN-2 is a selective inhibitor of ketohexokinase with an IC50 value of 0.45 μM.

KHK-IN-1 (KHK-IN-8) is a selective and cell membrane permeable inhibitor of ketohexokinase (KHK, IC50=12 nM; F=34%). KHK-IN-1 inhibits F1P production in HepG2 cell lysates with IC50 of 400 nM. KHK-IN-1 has potential for the study of obesity and diabetes.

KHK-IN-1 hydrochloride is a selective, cell-permeable, and efficient hexokinase (KHK) inhibitor, useful for studying diabetes and obesity.

KHK-IN-5 (Compound 18), a KHK inhibitor, is employed in the study of nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and type 2 diabetes (T2DM).

KHK-IN-6 (compound 33) acts as a KHK inhibitor with an IC50 of 0.6nM.

KHK-IN-7 (compound 2) is an inhibitor of ketohexokinase (KHK) and is utilized in research related to metabolic disorders.

KHK-IN-4 (compound 14) is a potent inhibitor of ketohexokinase (KHK), suitable for researching fructose metabolism diseases [1].

KHK-6 is an inhibitor of serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1), with an IC50 of 20 nM. This compound enhances cytokine production induced by CD3/CD28 and upregulates the expression of CD69, CD25, and HLA-DR markers on CD4+ and CD8+ T cells. Additionally, KHK-6 augments the T cell-mediated cytotoxicity against SKOV3 and A549 cells.

KHK-2898 is a human-derived antibody expressed in CHO cells, targeting CD98. It features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For its isotype control, please refer to HumanIgG1kappa, Isotype Control.

KHK-2866 is a human-derived antibody expressed in CHO cells, specifically targeting HBEGF. The predicted molecular weight (MW) of KHK-2866 is 145 kDa.

KHKI-01215 is an effective NUAK2 inhibitor with anticancer activity, inhibiting the proliferation of SW480 cancer cells and inducing apoptosis in SW480 cells. KHKI-01215 is used for cancer research.

KHKI-01128 is a NUAK2 inhibitor with an IC50 of 0.024 μM. It demonstrates effective anticancer activity against SW480 colorectal cancer cells.

Evocalcet (KHK7580) has an activating effect on the calcium-sensing receptor (CaSR).

Ketohexokinase inhibitor 1 is a ketohexokinase inhibitor (IC50s: 8.4 nM and 66 nM for KHK-C and KHK-A, respectively).

BI-9787 is a zwitterionic inhibitor of ketohexokinase (KHK), demonstrating IC50 values of 12 nM for hKHK-A and 12.8 nM for hKHK-C. It exhibits good metabolic stability in rat hepatocytes and favorable pharmacokinetic properties in vivo in rats.

Brodalumab (AMG 827) is a human monoclonal IgG2 antibody targeting the interleukin 17 receptor (IL-17R), commonly used as an immunosuppressant in treating psoriasis.

Rocatinlimab (AMG 451) (KHK4083) is a fully human, non-fucosylated IgG1 anti-OX40 monoclonal antibody indicated for atopic dermatitis (AD) research [1].

KHK-IN-3 (Example 1), a ketohexokinase (KHK) inhibitor, plays a crucial role in the study of various diseases including kidney disease, nonalcoholic steatohepatitis (NASH), diabetes, and heart failure. KHK, a pivotal rate-limiting enzyme and fructokinase, facilitates the metabolism of fructose by catalyzing the transformation of fructose into fructose-1-phosphate (FIP) utilizing ATP. This process lacks feedback inhibition, leading to the buildup of metabolites involved in lipogenesis, gluconeogenesis, and oxidative phosphorylation [1].